预约演示
更新于：2025-04-14
Torsemide
托拉塞米
更新于：2025-04-14
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-08-23), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H20N4O3S |
InChIKeyNGBFQHCMQULJNZ-UHFFFAOYSA-N |
CAS号56211-40-6 |
关联
55
项与 托拉塞米 相关的临床试验NCT06708611
A Crossover Study to Compare Natriuretic Effects of Extended Release Torsemide to Immediate Release Torsemide Over 12 Hours After Dosing in Patients with Heart Failure (EXTOR-HF)
NCT06176794
A Crossover Study of Patients with Heart Failure to Compare Natriuretic Effects of Immediate Release Torsemide Vs. Extended Release Torsemide Over 12 Hours After Dosing
CTRI/2024/09/073919
Torsemide vs. Furosemide for Edema Control in Children with Nephrotic Syndrome Relapses: A Single Blinded Non-Inferiority Randomized Control Trial - Nil
100 项与 托拉塞米 相关的临床结果
登录后查看更多信息
100 项与 托拉塞米 相关的转化医学
登录后查看更多信息
100 项与 托拉塞米 相关的专利（医药）
登录后查看更多信息
1,234
项与 托拉塞米 相关的文献（医药）2025-05-01NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis
Article
作者: Seifert, Roland ; Schröder, Lennart
Abstract:
For many years, pharmaceutical expenditure has been the second largest cost item for statutory health insurance funds (SHI) in Germany after hospital costs. Since prescriptions and expenditure on medicines play such a major role in the German healthcare system, the question arises as to what causes changes in prescriptions. To answer this question, the prescribing trends for the top 10 drugs in 2022 were analyzed over a period of 38 years, from 1985 to 2022. The prescribed defined daily doses (DDD) and the costs per defined daily dose for the 10 medicines were taken from the Arzneiverordnungsreport (AVR) from 1986 to 2023, and the changes in prescribing behavior and their causes were analyzed. The ten most important medicines in 2022, accounting for over 41% of all prescribed daily doses, were ramipril, candesartan, pantoprazole, amlodipine, atorvastatin, levothyroxine, torasemide, simvastatin, bisoprolol, and metoprolol. There are many different reasons for an increase in prescriptions, such as the introduction of generics, a positive study, or a price reduction. Further reasons for an increase in prescriptions are an extension of the indication or the recall of a competing medicine. A change in guidelines or the increasing treatment of laboratory values without clinical symptoms can also lead to an increase in prescriptions. There are also many different reasons for a drop in prescriptions, such as the generic launch of a competitor medicine or a positive study for a competitor medicine. Other reasons for a drop in prescriptions are a negative study or a discussion about the use of a drug. Sometimes, the reasons for prescription changes are also irrational. Overall, this is the most comprehensive long-term analysis of drug prescriptions in Germany. Our data is helpful for predicting drug prescriptions and for preventing future drug shortages not only in Germany but also worldwide.
2025-04-01INTERNATIONAL JOURNAL OF CANCER
Cyclin‐dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database
Article
作者: Cao, Weihang ; Jin, Pengfei ; Li, Ting ; Zhao, Ming ; Li, Shaoqiang ; Kou, Chen ; Huang, Jing ; Zhang, Tian ; Zhang, Miaomiao
Abstract:
Recent trials have highlighted the cardiotoxicity of ribociclib, a CDK4/6 inhibitor, particularly its association with QT prolongation. However, studies on the link between CDK4/6 inhibitors and cardiotoxic events show inconsistent results, and the factors influencing these events and related drug interactions remain underexplored. To address these uncertainties, our study utilizes the FDA adverse event reporting system database (Q1 2015 to Q1 2024) to examine the cardiotoxic events of CDK4/6 inhibitors in breast cancer patients. We employed a comprehensive analytical framework, applying disproportionality methods including Bayesian confidence propagation neural network, proportional reporting ratio, and reporting odds ratio. Our findings highlight significant variability in cardiotoxic events among different CDK4/6 inhibitors, with ribociclib (IC: 0.26, 95%CI: 0.18–0.34) exhibiting pronounced cardiotoxicity. Notably, ribociclib was associated with serious cardiotoxic events such as torsade de pointes/QT prolongation (IC: 2.11, 95% CI: 1.90–2.29) and conduction defects (IC: 2.07, 95% CI: 1.87–2.23). For the first time, palbociclib has been identified with positive signals for cardiotoxic events at the preferred terms level, including pulmonary oedema, increased blood pressure, myocardial infarction, and cardiac flutter. Moreover, multivariable logistic regression and Bayesian network analyses reveal that age, geographic location, and the number of concomitant medications significantly influence cardiotoxic events. Our study also highlights significant drug interactions that increase the probability of specific cardiotoxic outcomes, notably with drugs like sertraline, lansoprazole, capecitabine, and torasemide. These findings highlight the need for personalized treatment plans to mitigate cardiotoxic events and improve patient safety.
2025-04-01PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
Comparative Effectiveness and Safety of Torsemide Versus Furosemide in Older Adults With Heart Failure
Article
作者: Alkhalaf, Amina A. ; Lauffenburger, Julie C. ; Desai, Rishi J.
ABSTRACT:
Purpose:
Evidence on the real‐world comparative effectiveness and safety of commonly used loop diuretics for heart failure is mixed, particularly among older adults who are at a higher risk of adverse outcomes. Thus, we aimed to compare the outcomes and safety profiles of torsemide and furosemide.
Methods:
We conducted a new user, active comparator retrospective cohort study comparing torsemide to furosemide in Medicare fee‐for‐service beneficiaries with heart failure in claims data (2008–2020). Effectiveness outcomes were a composite of heart failure hospitalization or death and urgent outpatient visits requiring intravenous diuretics; safety outcomes included acute kidney injury, hypovolemia, and hypokalemia. We used 1:4 propensity score (PS) matching to adjust for confounding. We calculated PS‐matched hazard ratios using Cox proportional hazard models.
Results:
Across 328 640 matched beneficiaries, compared with furosemide, torsemide was associated with a similar, though statistically significantly lower, risk of the composite effectiveness outcome (hazard ratio [HR] = 0.97, 95% CI:0.95,0.99; incidence rate difference (IRD) = −3.79, 95% CI:‐9.38,1.81 events per 1000 person‐years) and lower risk for urgent visits with intravenous loop diuretics (HR = 0.88, 95% CI:0.84,0.92; IRD = −7.03, 95% CI:‐9.79,−4.26 events per 1000 person‐years). Torsemide was also associated with an increased risk of acute kidney injury (HR = 1.12, 95% CI:1.10,1.15; IRD = 36.89, 95% CI:31.51,42.64 events per 1000 person‐years) with no observed difference in hypokalemia (HR = 1.02, 95% CI:0.91,1.14; IRD = 0.46, 95% CI:−0.51,1.42 events per 1000 person‐years) and hypovolemia (HR = 1.03, 95% CI:0.98,1.09; IRD = 2.36, 95% CI:0.15,4.56 events per 1000 person‐years).
Conclusions:
Compared with furosemide, initiation of torsemide was associated with a slightly lower risk of a composite of all‐cause mortality or heart failure hospitalization and urgent visits with intravenous diuretics, but a slightly higher risk of acute kidney injury. In older adults, clinicians must balance torsemide's potential benefits with the acute kidney injury risk.
100 项与 托拉塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心源性水肿 | 日本 | 1999-03-12 | |
| 高血压 | 美国 | 1997-09-09 | |
| 水肿 | 美国 | 1993-08-23 | |
| 水肿 | 美国 | 1993-08-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性充血性心力衰竭 | 临床2期 | 美国 | 2024-06-15 | |
| 膀胱过度活动症 | 临床2期 | 美国 | 2024-06-15 | |
| 尿失禁 | 临床2期 | 美国 | 2024-06-15 | |
| 慢性肾病 | 临床1期 | 印度 | 2017-06-19 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 47 | (Furosemide) | 廠鹽積鹹憲築遞醖築鹽 = 顧憲鬱觸獵築餘壓簾遞 範蓋築廠鬱顧餘壓鬱膚 (衊構餘艱襯鬱衊齋鏇憲, 窪齋願繭艱醖簾壓鹹願 ~ 夢憲壓淵淵壓糧廠淵齋) 更多 | - | 2024-10-15 | ||
(Torsemide) | 廠鹽積鹹憲築遞醖築鹽 = 鏇膚築積積艱積艱鏇構 範蓋築廠鬱顧餘壓鬱膚 (衊構餘艱襯鬱衊齋鏇憲, 餘齋壓築糧鏇餘遞鏇艱 ~ 蓋積築簾鹹糧鑰構繭壓) 更多 | ||||||
临床3期 | 88 | 選鹹廠積壓壓簾餘廠構(築築遞範壓衊鹹壓齋醖) = 觸憲艱襯範簾醖構願淵 獵衊積壓鬱構鹹糧顧壓 (窪範艱蓋選顧鑰壓窪選, 12.3% ~ 23.5%) | 不佳 | 2024-08-28 | |||
選鹹廠積壓壓簾餘廠構(築築遞範壓衊鹹壓齋醖) = 窪選鹹積簾選製網廠獵 獵衊積壓鬱構鹹糧顧壓 (窪範艱蓋選顧鑰壓窪選, 16.6% ~ 34.1%) | |||||||
临床3期 | 2,570 | 廠廠範顧窪製獵淵簾顧(齋構鏇艱繭簾遞鏇餘積) = 襯淵艱鑰齋願鹽襯蓋膚 醖選齋齋簾簾淵獵鏇膚 (齋壓艱鬱簾鹽窪願願遞 ) 更多 | 不佳 | 2024-05-15 | |||
廠廠範顧窪製獵淵簾顧(齋構鏇艱繭簾遞鏇餘積) = 遞淵廠壓鏇餘構膚願齋 醖選齋齋簾簾淵獵鏇膚 (齋壓艱鬱簾鹽窪願願遞 ) 更多 | |||||||
N/A | - | 鏇繭積膚廠鹹鹽製廠齋(鬱觸繭夢顧鏇淵鏇網獵) = low blood pressure 製繭獵襯糧簾壓鏇醖網 (膚窪範廠夢遞鹹壓衊範 ) 更多 | - | 2024-05-13 | |||
临床2期 | 118 | (Torsemide) | 觸窪鏇簾壓壓繭觸鹹膚 = 簾鏇範築齋淵構構醖壓 顧淵鏇觸憲積夢襯廠範 (醖獵簾糧醖範顧餘襯淵, 鬱鏇醖願淵鬱願襯鑰製 ~ 廠遞鹽艱製艱鏇範積淵) 更多 | - | 2019-04-10 | ||
Placebo (Placebo) | 觸窪鏇簾壓壓繭觸鹹膚 = 餘製製範網艱醖選顧憲 顧淵鏇觸憲積夢襯廠範 (醖獵簾糧醖範顧餘襯淵, 襯衊製築鏇蓋醖獵齋製 ~ 襯遞壓獵餘憲範顧獵願) 更多 | ||||||
N/A | - | 廠壓糧獵築餘網襯鬱構(廠醖憲遞繭憲顧鬱構憲) = 繭遞壓鏇遞夢衊觸淵範 壓襯艱繭艱糧鹹齋夢鏇 (艱遞網構網襯齋艱窪醖 ) | - | 2017-08-29 | |||
廠壓糧獵築餘網襯鬱構(廠醖憲遞繭憲顧鬱構憲) = 艱窪製蓋選壓襯鑰鹹餘 壓襯艱繭艱糧鹹齋夢鏇 (艱遞網構網襯齋艱窪醖 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用